A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Summary

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or without prediabetes or T2DM).

Timeline

Start

2016-09

Primary completion

2017-06

Completion

2017-06

Drugs

Indications